Connective tissue diseases and liver

Yıl 2017, Cilt: 9 Sayı: 2, 38 - 41, 01.08.2017

Fatih Öner Kaya Gülbüz Sezgin Selim Nalbant

Öz

The liver is an organ that is affected by both metabolic and inflammatory events in general physiognomy. Therefore, it is unthinkable not to be affected by connective tissue diseases. However, this interaction is often overlooked. This interaction can be summarized as: liver involvement due to systemic connective tissue diseases, autoimmune liver diseases and effects on the liver of drugs used in these diseases. Though it is not always possible to distinguish this triple interaction from one another, it is an important factor that should be considered in terms of the success of the treatment.

Anahtar Kelimeler

connective tissue diseases, liver

Bağ dokusu hastalıkları ve karaciğer

Öz

Karaciğer genel fizyonomi içerisinde hem metabolik hem de inflamatuvar olaylardan etkilenen bir organdır. Dolayısıyla, bağ dokusu hastalıklarından etkilenmemesi düşünülemez. Ancak, bu etkileşim çoğu zaman göz ardı edilmektedir. Bu etkileşim: Sistemik bağ dokusu hastalıklarına bağlı karaciğerin etkilenmesi, otoimmün karaciğer hastalıkları ve bu hastalıklarda kullanılan ilaçların karaciğer üzerindeki etkileri şeklinde özetlenebilir. Her zaman bu üçlü etkileşimi bir birinden ayırt etmek mümkün olmasa da tedavinin başarısı açısından dikkat edilmesi gereken önemli bir faktördür.

Anahtar Kelimeler

bağ dokusu hastalıkları, karaciğer

Kaynakça

• 1. Carlo Selmi, Maria De Santis and M Eric Gershwin. Liver involvement in subjects with rheumatic disease. Selmi et al. Arthritis Research & Therapy 2011, 13:226.
• 2. Katarina Sedej, Nataša Toplak, Marina Praprotnik, Bo štjan Luzar, Jernej Brecelj and Tadej Avčin. Autoimmune hepatitis as a presenting manifestation of mixed connective tissue disease in a child Case report and review of the literature . Sedej et al. Pediatric Rheumatology (2015) 13:47.
• 3. Ortega-Hernandez OD, Shoenfeld Y. Mixed connective tissue disease: an overview of clinical manifestations, diagnosis and treatment. Best Pract Res Clin Rheumatol. 2012;26:61–72.
• 4. Manns MP, Czaja AJ, Gorham JD, Krawitt EL, Mieli-Vergani G, Vergani D, et al. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010;51:2193–213.
• 5. Teufel A, Weinmann A, Kahaly GJ, Centner C, Piendl A, Wörns M, et al. Concurrent autoimmune diseases in patients with autoimmune hepatitis. J Clin Gastroenterol. 2010;44:208–213.
• 6. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31:929–938.
• 7. Abraham S, Begum S, Isenberg D. Hepatic manifestations of autoimmune rheumatic diseases. Ann Rheum Dis. 2004;63:123–129.
• 8. Selmi C, De Santis M, Gershwin ME. Liver involvement in subjects with rheumatic disease. Arthritis Res Ther. 2011;13:226.
• 9. Soultati A, Dourakis S. Hepatic manifestations of autoimmune rheumatic diseases. Ann Gastroenterol. 2005;18:309–324.
• 10. Min JK, Han NI, Kim JA, Lee YS, Cho CS, Kim HY. A case of cholestatic autoimmune hepatitis and acute liver failure: an unusual hepatic manifestation of mixed connective tissue disease and Sjögren’s syndrome. J Korean Med Sci. 2001;16:512–515.
• 11. Acute liver injury associated with nonsteroidal anti-inflammatory drugs and the role of risk factors.Garcia Rodriguez et al. Arch Intern Med 1994;154:311.
• 12. Ibuprofen-induced hepatotoxicity in patients with chronic hepatitis C: a case series.Riley et al Am J Gastroenterol 1998;93:1563-1565
• 13. Diclofenac-associated hepatotoxicity: analysis of 180 cases reported to the Food and Drug Administration as adverse reactions.Banks et al. Hepatology 1995;22:820-827.
• 14. Baun J, Rau R. An update on methotrexate. Curr Opin Rheumatol, 2009; 21: 216-223.
• 15. Hider SL, Bruce IN, Thomson W. The pharmacogenetics of methotrexate. Rheumatol, 2007; 46: 1520-4.
• 16. Kremer JM. Methotrexate pharmacogenomics. Ann Rheum Dis, 2010;22: 1121-1123.
• 17. Mc Cune WJ, Friedman AW. Immunosuppressive drug therapy for rheumatic disease. Curr Opin Rheumatol, 1993; 5:282-292.
• 18. Parke A, West B. Hydroxychloroquine in pregnant patients with SLE. J Rheumatol, 1996;23: 1715-8.
• 19. Plosker GL, Croom KF. Sulfasalazine; A review of its use in the management of rheumatoid arthritis. Drugs, 2005;65: 1825-1849.
• 20. Saag KG, Teng GG, Patkar NM and et al. American College of Rheumatology 2008 Recommendations for the use of nonbiologic and biologic diseasemodifying antirheumatic drugs in rheumatoid arthritis. Arthritis & Rheum, 2008;59: 762-784.
• 21. Toloza SMA, Alarcon GS. Methotrexate and leflunamid: Use in the treatment of rheumatoid arthritis and other rheumatic disorders. In arthritis and allied conditions, text book of rheumatology, 15th Ed, Kopman WJ, Moreland LW, Lippincott Williams & Wilkins, Philadelphia, Vol 1;2005:705- 738.
• 22. Alstead EM, Ritchie JK, Lennard-Jones JE, et al. Safety of azathioprine in pregnancy in inflammatory bowel disease. Gastroenterology 1990; 99: 443- 446.